BeOne Medicines Ltd. — Director's Dealing 2019

May 23, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2019-05-21

Reporting Person: Liang Howard (CFO & Chief Strategy Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-05-21	American Depositary Shares	M	23200	$6.50	Acquired	23200	Direct
2019-05-21	American Depositary Shares	S	23200	$130.2095	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-05-21	Share Option (Right to Buy)	$0.5	M	301600	Acquired	2025-07-01	Ordinary Shares (301600.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	52338	Direct

Footnotes

F1: Each American Depositary Share ("ADS") represents 13 Ordinary Shares.

F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.79, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.

F4: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F5: These securities vest over a four-year period as follows: 25% on July 15, 2016, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon a sale event or certain termination events.